Xenon PharmaceuticalsXENE
Market Cap: $2.91B
About: Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company committed to developing therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system, or CNS, conditions. The product candidates of the group include XEN1101, XEN901, and XEN496 for Epilepsy, and Nav1.7 oral inhibitors for Pain. Geographically the activities are carried out throughout Canada.
Employees: 259
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
198% more call options, than puts
Call options by funds: $10.5M | Put options by funds: $3.54M
8% more repeat investments, than reductions
Existing positions increased: 77 | Existing positions reduced: 71
0.35% more ownership
Funds ownership: 97.85% [Q1] → 98.2% (+0.35%) [Q2]
3% less funds holding
Funds holding: 217 [Q1] → 210 (-7) [Q2]
9% less capital invested
Capital invested by funds: $3.18B [Q1] → $2.89B (-$288M) [Q2]
20% less funds holding in top 10
Funds holding in top 10: 10 [Q1] → 8 (-2) [Q2]
25% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 28
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
5 analyst ratings
RBC Capital Brian Abrahams 52% 1-year accuracy 39 / 75 met price target | 43%upside $55 | Outperform Reiterated | 3 Sept 2024 |
Needham Serge Belanger 41% 1-year accuracy 47 / 114 met price target | 56%upside $60 | Buy Maintained | 12 Aug 2024 |
Cantor Fitzgerald Josh Schimmer 71% 1-year accuracy 41 / 58 met price target | 69%upside $65 | Overweight Reiterated | 9 Aug 2024 |
Wedbush Laura Chico 44% 1-year accuracy 33 / 75 met price target | 27%upside $49 | Outperform Maintained | 9 Aug 2024 |
RBC Capital Brian Abrahams 52% 1-year accuracy 39 / 75 met price target | 43%upside $55 | Outperform Reiterated | 18 Jun 2024 |
Financial journalist opinion
Based on 4 articles about XENE published over the past 30 days